Last reviewed · How we verify

Tysabri — Competitive Intelligence Brief

Tysabri (NATALIZUMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrin Receptor Antagonist [EPC]. Area: Immunology.

marketed Integrin Receptor Antagonist [EPC] α4β1 and α4β7 integrins Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Tysabri (NATALIZUMAB) — Biogen Idec. Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tysabri TARGET NATALIZUMAB Biogen Idec marketed Integrin Receptor Antagonist [EPC] α4β1 and α4β7 integrins 2004-01-01
Entyvio vedolizumab Takeda marketed Integrin Receptor Antagonist [EPC] Integrin alpha-4/beta-7
TYRUKO NATALIZUMAB-SZTN SANDOZ INC marketed Integrin Receptor Antagonist [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrin Receptor Antagonist [EPC] class)

  1. Biogen Idec · 1 drug in this class
  2. SANDOZ INC · 1 drug in this class
  3. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tysabri — Competitive Intelligence Brief. https://druglandscape.com/ci/natalizumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: